Stockreport
BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology [Reuters]

US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
PDF
BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology | Reuters Reuters Staff 1 Min Read April 16 (Reuters) - XBiotech Inc: * XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY * XBIOTECH INC - CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved.
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | XBIT | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
XBIT alerts
XBIT alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
XBIT alerts
High impacting XBIOTECH INC COMMON news events
Weekly update
A roundup of the hottest topics
XBIT
NEWS
NEWS
- XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology[GlobeNewswire]
- XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer[GlobeNewswire]
- XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa[GlobeNewswire]
- XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus[GlobeNewswire]
- More
XBIT
SEC Filings
SEC Filings
- 4/11/18 - Form 8-K
- 3/26/18 - Form 4
- 3/23/18 - Form 8-K
- XBIT's page on the SEC website
- More